Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity

Journal of Immunology

Volumn 191, Issue 10, 2013, Pages 5097-5106

  Chen, Shuming ^a   Li, Yili ^b   Depontieu, Florence R ^a   McMiller, Tracee L ^a   Michelle English, A ^c   Shabanowitz, Jeffrey ^c   Kos, Ferdynand ^a   Sidney, John ^d   Sette, Alessandro ^d   Rosenberg, Steven A ^e   Hunt, Donald F ^c   Mariuzza, Roy A ^b   Topalian, Suzanne L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERED PEPTIDE LIGAND; EPITOPE; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100 PEPTIDE VACCINE; HLA DR4 ANTIGEN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; MELANOCYTE PROTEIN PMEL 17;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOREACTIVITY; MELANOMA; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; T LYMPHOCYTE; VACCINE PRODUCTION; WILD TYPE; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE; ULTRASTRUCTURE; X RAY DIFFRACTION;

CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GP100 MELANOMA ANTIGEN; HLA-DR4 ANTIGEN; HUMANS; MELANOMA; RECEPTORS, ANTIGEN, T-CELL; X-RAY DIFFRACTION;

EID: 84887431966     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300467     Document Type: Article

References (62)

1. Balch, C. M., J. E. Gershenwald, S. J. Soong, J. F. Thompson, M. B. Atkins, D. R. Byrd, A. C. Buzaid, A. J. Cochran, D. G. Coit, S. Ding, et al. 2009. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27:6199-6206.
2. Heemskerk, B., K. Liu, M. E. Dudley, L. A. Johnson, A. Kaiser, S. Downey, Z. Zheng, T. E. Shelton, K. Matsuda, P. F. Robbins, et al. 2008. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum. Gene Ther. 19:496-510.
3. Hodi, F. S., S. J. O'Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723.
4. Topalian, S. L., F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:2443-2454.
5. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:2455-2465.
6. Li, B., M. Van Roey, C. Wang, T. H. Chen, A. Korman, and K. Jooss. 2009. Antiprogrammed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin. Cancer Res. 15:1623-1634.
7. Hurwitz, A. A., T. F. Yu, D. R. Leach, and J. P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95:10067-10071.
8. Schwartzentruber, D. J., D. H. Lawson, J. M. Richards, R. M. Conry, D. M. Miller, J. Treisman, F. Gailani, L. Riley, K. Conlon, B. Pockaj, et al. 2011. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364:2119-2127.
9. Kawakami, Y., P. F. Robbins, and S. A. Rosenberg. 1996. Human melanoma antigens recognized by T lymphocytes. Keio J. Med. 45:100-108.
10. Dudley, M. E., J. R. Wunderlich, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. M. Sherry, F. M. Marincola, S. F. Leitman, C. A. Seipp, et al. 2002. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25:243-251.
11. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968.
12. Pardoll, D. M., and S. L. Topalian. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588-594.
13. Halder, T., G. Pawelec, A. F. Kirkin, J. Zeuthen, H. E. Meyer, L. Kun, and H. Kalbacher. 1997. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 57:3238-3244.
14. Touloukian, C. E., W. W. Leitner, S. L. Topalian, Y. F. Li, P. F. Robbins, S. A. Rosenberg, and N. P. Restifo. 2000. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J. Immunol. 164:3535-3542.
15. Kierstead, L. S., E. Ranieri, W. Olson, V. Brusic, J. Sidney, A. Sette, Y. L. Kasamon, C. L. Slingluff, Jr., J. M. Kirkwood, and W. J. Storkus. 2001. gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br. J. Cancer 85:1738-1745.
16. Phan, G. Q., C. E. Touloukian, J. C. Yang, N. P. Restifo, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, C. A. Seipp, L. J. Freezer, et al. 2003. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. 26:349-356.
17. *0201-binding residues. J. Immunol. 157:2539-2548.
18. Salgaller, M. L., F. M. Marincola, J. N. Cormier, and S. A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:4749-4757.
19. Clay, T. M., M. C. Custer, M. D. McKee, M. Parkhurst, P. F. Robbins, K. Kerstann, J. Wunderlich, S. A. Rosenberg, and M. I. Nishimura. 1999. Changes in the fine specificity of gp100 (209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol. 162:1749-1755.
20. Dudley, M. E., M. I. Nishimura, A. K. Holt, and S. A. Rosenberg. 1999. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J. Immunother. 22:288-298.
21. Van Stipdonk, M. J., D. Badia-Martinez, M. Sluijter, R. Offringa, T. Van Hall, and A. Achour. 2009. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res. 69:7784-7792.
22. Rammensee, H. G., T. Friede, and S. Stevanoviíc. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228.
23. Sette, A., J. Sidney, C. Oseroff, M. F. Del Guercio, S. Southwood, T. Arrhenius, M. F. Powell, S. M. Colón, F. C. Gaeta, and H. M. Grey. 1993. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J. Immunol. 151:3163-3170.
24. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74:197-203.
25. Hammer, J., C. Belunis, D. Bolin, J. Papadopoulos, R. Walsky, J. Higelin, W. Danho, F. Sinigaglia, and Z. A. Nagy. 1994. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. Proc. Natl. Acad. Sci. USA 91:4456-4460.
26. Depontieu, F. R., J. Qian, A. L. Zarling, T. L. McMiller, T. M. Salay, A. Norris, A. M. English, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and S. L. Topalian. 2009. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc. Natl. Acad. Sci. USA 106:12073-12078.
27. Udeshi, N. D., P. D. Compton, J. Shabanowitz, D. F. Hunt, and K. L. Rose. 2008. Methods for analyzing peptides and proteins on a chromatographic timescale by electron-transfer dissociation mass spectrometry. Nat. Protoc. 3:1709-1717.
28. Chi, A., C. Huttenhower, L. Y. Geer, J. J. Coon, J. E. Syka, D. L. Bai, J. Shabanowitz, D. J. Burke, O. G. Troyanskaya, and D. F. Hunt. 2007. Analysis of phosphorylation sites on proteins from Saccharomyces cerevisiae by electron transfer dissociation (ETD) mass spectrometry. Proc. Natl. Acad. Sci. USA 104:2193-2198.
29. Geer, L. Y., S. P. Markey, J. A. Kowalak, L. Wagner, M. Xu, D. M. Maynard, X. Yang, W. Shi, and S. H. Bryant. 2004. Open mass spectrometry search algorithm. J. Proteome Res. 3:958-964.
30. Wang, R. F., X. Wang, A. C. Atwood, S. L. Topalian, and S. A. Rosenberg. 1999. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284:1351-1354.
31. Sidney, J., S. Southwood, C. Oseroff, M. F. Del Guercio, A. Sette, and H. M. Grey. 2001. Measurement of MHC/peptide interactions by gel filtration. Curr. Protoc. Immunol. Chapter 18: Unit 18.13.
32. Greenbaum, J., J. Sidney, J. Chung, C. Brander, B. Peters, and A. Sette. 2011. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 63:325-335.
33. Southwood, S., J. Sidney, A. Kondo, M. F. Del Guercio, E. Appella, S. Hoffman, R. T. Kubo, R. W. Chesnut, H. M. Grey, and A. Sette. 1998. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160:3363-3373.
34. Gulukota, K., J. Sidney, A. Sette, and C. De Lisi. 1997. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267:1258-1267.
35. Cheng, Y., and W. H. Prusoff. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108.
36. Frayser, M., A. K. Sato, L. Xu, and L. J. Stern. 1999. Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Protein Expr. Purif. 15:105-114.
37. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology. Vol. 276: Macromolecular Crystallography, part A. C. W. Carter, Jr., and R. M. Sweet, eds. Academic Press, New York. p. 307-326.
38. Storoni, L. C., A. J. McCoy, and R. J. Read. 2004. Likelihood-enhanced fast rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60:432-438.
39. Bolin, D. R., A. L. Swain, R. Sarabu, S. J. Berthel, P. Gillespie, N. J. Huby, R. Makofske, L. Orzechowski, A. Perrotta, K. Toth, et al. 2000. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. J. Med. Chem. 43:2135-2148.
40. Brünger, A. T., P. D. Adams, G. M. Clore, W. L. De Lano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, et al. 1998. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54:905-921.
41. McRee, D. E. 1999. XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125:156-165.
42. Laskowski, R. A., M. W. MacArthur, D. S. Moss, and J. M. Thornton. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:283-291.
43. Li, Y., F. R. Depontieu, J. Sidney, T. M. Salay, V. H. Engelhard, D. F. Hunt, A. Sette, S. L. Topalian, and R. A. Mariuzza. 2010. Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. J. Mol. Biol. 399:596-603.
44. Hammer, J., F. Gallazzi, E. Bono, R. W. Karr, J. Guenot, P. Valsasnini, Z. A. Nagy, and F. Sinigaglia. 1995. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 181:1847-1855.
45. *0401): insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 195:571-581.
46. *0401) subjects is associated with a restricted T cell receptor repertoire. J. Clin. Invest. 100:339-349.
47. *0401) complexed with a peptide from human collagen II. Immunity 7:473-481.
48. Yin, Y., Y. Li, M. C. Kerzic, R. Martin, and R. A. Mariuzza. 2011. Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J. 30:1137-1148.
49. Borbulevych, O. Y., F. K. Insaidoo, T. K. Baxter, D. J. Powell, Jr., L. A. Johnson, N. P. Restifo, and B. M. Baker. 2007. Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J. Mol. Biol. 372:1123-1136.
50. Johnson, L. A., R. A. Morgan, M. E. Dudley, L. Cassard, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, R. M. Sherry, J. R. Wunderlich, et al. 2009. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546.
51. McMahan, R. H., J. A. McWilliams, K. R. Jordan, S. W. Dow, D. B. Wilson, and J. E. Slansky. 2006. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J. Clin. Invest. 116:2543-2551.
52. Vita, R., L. Zarebski, J. A. Greenbaum, H. Emami, I. Hoof, N. Salimi, R. Damle, A. Sette, and B. Peters. 2010. The immune epitope database 2.0. Nucleic Acids Res. 38 (Database issue):D854-D862.
53. Bielekova, B., B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J. A. Frank, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:1167-1175.
54. Pöhlmann, T., R. A. Böckmann, H. Grubmüller, B. Uchanska-Ziegler, A. Ziegler, and U. Alexiev. 2004. Differential peptide dynamics is linked to major histocompatibility complex polymorphism. J. Biol. Chem. 279:28197-28201.
55. Insaidoo, F. K., O. Y. Borbulevych, M. Hossain, S. M. Santhanagopolan, T. K. Baxter, and B. M. Baker. 2011. Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design. J. Biol. Chem. 286:40163-40173.
56. Baker, B. M., D. R. Scott, S. J. Blevins, and W. F. Hawse. 2012. Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism. Immunol. Rev. 250:10-31.
57. Allerbring, E. B., A. D. Duru, H. Uchtenhagen, C. Madhurantakam, M. B. Tomek, S. Grimm, P. A. Mazumdar, R. Friemann, M. Uhlin, T. Sandalova, et al. 2012. Unexpected T-cell recognition of an altered peptide ligand is driven by reversed thermodynamics. Eur. J. Immunol. 42:2990-3000.
58. Yin, Y., Y. Li, and R. A. Mariuzza. 2012. Structural basis for self-recognition by autoimmune T-cell receptors. Immunol. Rev. 250:32-48.
59. Deng, L., R. J. Langley, P. H. Brown, G. Xu, L. Teng, Q. Wang, M. I. Gonzales, G. G. Callender, M. I. Nishimura, S. L. Topalian, and R. A. Mariuzza. 2007. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nat. Immunol. 8:398-408.
60. Deng, L., R. J. Langley, Q. Wang, S. L. Topalian, and R. A. Mariuzza. 2012. Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Va CDR3. Proc. Natl. Acad. Sci. USA 109:14960-14965.
61. Hahn, M., M. J. Nicholson, J. Pyrdol, and K. W. Wucherpfennig. 2005. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol. 6:490-496.
62. Harkiolaki, M., S. L. Holmes, P. Svendsen, J. W. Gregersen, L. T. Jensen, R. McMahon, M. A. Friese, G. Van Boxel, R. Etzensperger, J. S. Tzartos, et al. 2009. T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity 30:348-357.